By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

US pharma group says patients who took Emraclidine in clinical trials failed to show a significant decline in symptoms ...

The other possibility is that M1 agonism is required for muscarinic drugs to work and this ... The best-case scenario would ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug. AbbVie ABBV shares are down 12.4%. In a statement ...

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...

AbbVie raised its annual profit forecast on Wednesday after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings ...

U.S. equities continued their post-election rally at midday, fueled by optimism that the new Trump administration will be a ...